Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT03416179
Registration number
NCT03416179
Ethics application status
Date submitted
21/12/2017
Date registered
31/01/2018
Date last updated
21/04/2023
Titles & IDs
Public title
A Study Evaluating Intensive Chemotherapy With or Without Glasdegib or Azacitidine With or Without Glasdegib In Patients With Previously Untreated Acute Myeloid Leukemia
Query!
Scientific title
A RANDOMIZED (1:1), DOUBLE-BLIND, MULTI-CENTER, PLACEBO CONTROLLED STUDY EVALUATING INTENSIVE CHEMOTHERAPY WITH OR WITHOUT GLASDEGIB (PF-04449913) OR AZACITIDINE (AZA) WITH OR WITHOUT GLASDEGIB IN PATIENTS WITH PREVIOUSLY UNTREATED ACUTE MYELOID LEUKEMIA
Query!
Secondary ID [1]
0
0
2017-002822-19
Query!
Secondary ID [2]
0
0
B1371019
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
BRIGHT AML1019
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Leukemia, Myeloid, Acute
0
0
Query!
Condition category
Condition code
Cancer
0
0
0
0
Query!
Leukaemia - Acute leukaemia
Query!
Cancer
0
0
0
0
Query!
Leukaemia - Chronic leukaemia
Query!
Cancer
0
0
0
0
Query!
Children's - Leukaemia & Lymphoma
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - glasdegib
Treatment: Drugs - daunorubicin + cytarabine
Treatment: Drugs - azacitidine
Treatment: Drugs - Placebo
Treatment: Drugs - Placebo
Treatment: Drugs - glasdegib
Treatment: Drugs - cytarabine
Treatment: Surgery - HSCT
Experimental: Arm A (Intensive Study) - Glasdegib + '7+3' Induction(s)
Placebo Comparator: Arm B (Intensive Study) - Placebo + '7+3' Induction(s)
Experimental: Arm A (Non-intensive study) - Glasdegib + azacitidine
Placebo Comparator: Arm B (Non-intensive study) - Placebo + azacitidine
Treatment: Drugs: glasdegib
Daily Glasdegib (100 mg, PO), beginning on Day 1 and is to continue up to 2 years post randomization.
Following consolidation therapy, glasdegib or placebo will be administered daily for up to 2 years after randomization or until they have minimal residual disease (MRD) negative disease, whichever comes first.
Daily Glasdegib (100 mg, PO) or matching placebo will continue throughout Induction(s) and Consolidation therapies regardless of dose modifications/delays in the chemotherapy.
Treatment: Drugs: daunorubicin + cytarabine
'7+3' (cytarabine 100 mg/m2, IV for 7 days by continuous infusion and daunorubicin 60 mg/m2 for 3 days).
If a second induction is needed, Investigators may choose either a 5 day cytarabine continuous infusion plus daunorubicin for 2 days ('5+2') or a 7 day cytarabine continuous infusion plus daunorubicin for 3 days ('7+3');
Treatment: Drugs: azacitidine
Azacitidine (75 mg/m2, SC or IV) daily for 7 days, in 28 day cycles for as long as they do not meet the criteria for disease progression, unacceptable toxicity, consent withdrawal, or death.
Treatment: Drugs: Placebo
Matching placebo (PO) given on Day 1 and is to continue up to 2 years post randomization. Following consolidation therapy, placebo will be administered daily for up to 2 years after randomization or until they have MRD negative disease, whichever comes first.
Daily placebo will continue throughout Induction(s) and Consolidation therapies regardless of dose modifications/delays in the chemotherapy.
Treatment: Drugs: Placebo
Matching placebo (PO) is to be administered by mouth daily beginning on Day 1 of chemotherapy and will continue if subjects demonstrate reasonable evidence of clinical benefit and do not meet the criteria for progression regardless of any delays/modifications in the chemotherapy treatment. Subjects will continue placebo until disease progression, unacceptable toxicity, consent withdrawal, or death, whichever comes first.
Treatment: Drugs: glasdegib
Glasdegib 100 mg PO QD is to be administered by mouth daily beginning on Day 1 of chemotherapy and will continue if subjects demonstrate reasonable evidence of clinical benefit and do not meet the criteria for progression regardless of any delays/modifications in the chemotherapy treatment.
Subjects will continue glasdegib until disease progression, unacceptable toxicity, consent withdrawal, or death, whichever comes first.
Treatment: Drugs: cytarabine
Consolidation with single agent cytarabine 3 g/m2 IV for adults <60 years and 1 g/m2 for adults 60 years over 3 BID on Days 1, 3, and 5, every 28 days for up to 4 cycles or alternative single agent cytarabine consolidation schedules may be used per local prescribing information.
Treatment: Surgery: HSCT
If required, and done per standard of care post Induction(s).
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Intervention code [2]
0
0
Treatment: Surgery
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Intensive Study: Overall Survival (OS)
Query!
Assessment method [1]
0
0
OS is defined as the time from the date of randomization to the date of death due to any cause. Participants last known to be alive were to be censored at the date of last contact.
Query!
Timepoint [1]
0
0
Baseline up to 25 months
Query!
Primary outcome [2]
0
0
Non-intensive Study: Overall Survival (OS)
Query!
Assessment method [2]
0
0
OS is defined as the time from the date of randomization to the date of death due to any cause. Participants last known to be alive were to be censored at the date of last contact.
Query!
Timepoint [2]
0
0
Baseline up to 25 months
Query!
Secondary outcome [1]
0
0
Intensive Study: Percentage of Participants Who Improved in Fatigue Score Measured by the MD Anderson Symptom Inventory -Acute Myelogenous Leukemia/Myelodysplastic Syndrome (MDASI-AML/MDS) Questionnaire
Query!
Assessment method [1]
0
0
MDASI-AML/MDS: consists of 23 items, 13-item core cancer symptoms (pain, fatigue, nausea, disturbed sleep, distress, shortness of breath, problem remembering, lack of appetite, drowsiness, dry mouth, sadness, vomiting, and numbness), 4-item AML/MDS specific symptoms (malaise, diarrhea, muscle weakness, and skin problems), and 6 areas of interference (general activity, mood, work, walking, relations with other people, and enjoyment of life). "Fatigue" was measured at the participants' worst level in last 24 hours by asking participants to respond to each item on an 0-10 numeric rating scale (NRS), where 0 = "not present" and 10 = "as bad as you can imagine". Percentage of participants who had improvement in "fatigue" symptoms reported in this outcome measure.
Query!
Timepoint [1]
0
0
Post-baseline up to Week 8
Query!
Secondary outcome [2]
0
0
Non-intensive Study: Percentage of Participants Who Improved in Fatigue Score Measured by the MDASI-AML/MDS Questionnaire at Week 12
Query!
Assessment method [2]
0
0
MDASI-AML/MDS: consists of 23 items, 13-item core cancer symptoms (pain, fatigue, nausea, disturbed sleep, distress, shortness of breath, problem remembering, lack of appetite, drowsiness, dry mouth, sadness, vomiting, and numbness), 4-item AML/MDS specific symptoms (malaise, diarrhea, muscle weakness, and skin problems), and 6 areas of interference (general activity, mood, work, walking, relations with other people, and enjoyment of life). "Fatigue" was measured at the participants' worst level in last 24 hours by asking participants to respond to each item on an 0-10 NRS, where 0 = "not present" and 10 = "as bad as you can imagine". Percentage of participants who had improvement in "fatigue" symptoms reported in this outcome measure.
Query!
Timepoint [2]
0
0
Post-baseline up to Week 12
Query!
Secondary outcome [3]
0
0
Intensive Study: Percentage of Participants With Complete Remission Without Negative Minimal Residual Disease (CRMRD-neg)
Query!
Assessment method [3]
0
0
Complete remission (CR) was defined based on 2017 European LeukemiaNet (ELN) recommendations. CR: Bone marrow blasts <5 percentage (%); absence of circulating blasts and blasts with Auer rods; absence of extramedullary disease; absolute neutrophil count (ANC) greater than equal to (>=) 1.0*10^9/Liter (L); platelet count >=100*10^9/L. CRMRD-neg: CR with negativity for a genetic marker by reverse transcription quantitative polymerase chain reaction (RT-qPCR), or CR with negativity by Multiparameter Flow Cytometry (MFC).
Query!
Timepoint [3]
0
0
Day 1 up to maximum of 2 years
Query!
Secondary outcome [4]
0
0
Non-intensive Study: Percentage of Participants With Complete Remission Without Negative Minimal Residual Disease (CRMRD-neg)
Query!
Assessment method [4]
0
0
CR was defined based on 2017 ELN recommendations. CR: Bone marrow blasts <5%; absence of circulating blasts and blasts with Auer rods; absence of extramedullary disease; ANC >=1.0*10^9/L; platelet count >=100*10^9/L. CRMRDneg: CR with negativity for a genetic marker by RT-qPCR, or CR with negativity by MFC.
Query!
Timepoint [4]
0
0
Day 1 up to maximum of 3 years
Query!
Secondary outcome [5]
0
0
Intensive Study: Percentage of Participants With Complete Remission Including Negative Minimal Residual Disease (CRMRD-neg)
Query!
Assessment method [5]
0
0
CR was defined based on 2017 ELN recommendations. CR: Bone marrow blasts <5%; absence of circulating blasts and blasts with Auer rods; absence of extramedullary disease; ANC >=1.0*10^9/L; platelet count >=100*10^9/L. CRMRDneg: CR with negativity for a genetic marker by RT-qPCR, or CR with negativity by MFC.
Query!
Timepoint [5]
0
0
Day 1 up to maximum of 2 years
Query!
Secondary outcome [6]
0
0
Non-intensive Study: Percentage of Participants With Complete Remission (CR) Including Negative Minimal Residual Disease (CRMRD-neg)
Query!
Assessment method [6]
0
0
CR was defined based on 2017 ELN recommendations. CR: Bone marrow blasts <5%; absence of circulating blasts and blasts with Auer rods; absence of extramedullary disease; ANC >=1.0*10^9/L; platelet count >=100*10^9/L. CRMRDneg: CR with negativity for a genetic marker by RT-qPCR, or CR with negativity by MFC.
Query!
Timepoint [6]
0
0
Day 1 up to maximum of 3 years
Query!
Secondary outcome [7]
0
0
Intensive Study: Percentage of Participants With Complete Remission With Incomplete Hematologic Recovery (CRi)
Query!
Assessment method [7]
0
0
CR was defined based on 2017 ELN recommendations. CR: MRD (positive or unknown), bone marrow blasts <5%; absence of circulating blasts and blasts with Auer rods; absence of extramedullary disease; ANC less than (<) 1.0*10^9/L; platelet count <100 × 10^9/L. CRi (included CR [includes CRMRD-neg]): not qualifying for CR, neutropenia <1.0*10^9/L or platelets <100*10^9, absence of extramedullary disease, and absence of blasts with Auer rods.
Query!
Timepoint [7]
0
0
Day 1 up to maximum of 2 years
Query!
Secondary outcome [8]
0
0
Non-intensive Study: Percentage of Participants With Complete Remission With Incomplete Hematologic Recovery (CRi)
Query!
Assessment method [8]
0
0
CR was defined based on 2017 ELN recommendations. CR: MRD (positive or unknown), bone marrow blasts <5%; absence of circulating blasts and blasts with Auer rods; absence of extramedullary disease; ANC <1.0*10^9/L; platelet count <100 × 10^9/L. CRi (included CR [includes CRMRD-neg]): not qualifying for CR, neutrophil <0.5*10^9/L or platelets <50*10^9, absence of extramedullary disease, and absence of blasts with Auer rods.
Query!
Timepoint [8]
0
0
Day 1 up to maximum of 3 years
Query!
Secondary outcome [9]
0
0
Intensive Study: Percentage of Participants With Morphologic Leukemia-free State (MLFS)
Query!
Assessment method [9]
0
0
MLFS was defined based on 2017 ELN recommendations. MLFS: MRD (positive or unknown), bone marrow blasts <5%, no hematologic recovery required, marrow should not be aplastic, at least 200 cells enumerated or cellularity absence of extramedullary disease >=10%, and absence of blasts with Auer rods.
Query!
Timepoint [9]
0
0
Day 1 up to maximum of 2 years
Query!
Secondary outcome [10]
0
0
Non-intensive Study: Percentage of Participants With Morphologic Leukemia-free State (MLFS)
Query!
Assessment method [10]
0
0
MLFS was defined based on 2017 ELN recommendations. MLFS: MRD (positive or unknown), bone marrow blasts <5%, no hematologic recovery required, marrow should not be aplastic, at least 200 cells enumerated or cellularity absence of extramedullary disease >=10%, and absence of blasts with Auer rods.
Query!
Timepoint [10]
0
0
Day 1 up to maximum of 3 years
Query!
Secondary outcome [11]
0
0
Intensive Study: Percentage of Participants With Partial Remission (PR)
Query!
Assessment method [11]
0
0
PR was defined based on 2017 ELN recommendations. PR: MRD (positive or unknown); bone marrow blasts - decrease to 5-25% and decrease of pre-treatment bone marrow blast percentage by at least 50%; neutrophil count >=1.0*10^9/L; and platelets count >=100*10^9/L.
Query!
Timepoint [11]
0
0
Day 1 up to maximum of 2 years
Query!
Secondary outcome [12]
0
0
Non-intensive Study: Percentage of Participants With Partial Remission (PR)
Query!
Assessment method [12]
0
0
PR was defined based on 2017 ELN recommendations. PR: MRD (positive or unknown); bone marrow blasts - decrease to 5-25% and decrease of pre-treatment bone marrow blast percentage by at least 50%; neutrophil count >=1.0*10^9/L; and platelets count >=100*10^9/L.
Query!
Timepoint [12]
0
0
Day 1 up to maximum of 3 years
Query!
Secondary outcome [13]
0
0
Non-intensive Study: Percentage of Participants With Complete Remission With Partial Hematologic Recovery (CRh)
Query!
Assessment method [13]
0
0
CRh: MRD (positive or unknown); bone marrow blasts <5%; assessed in non-intensive chemotherapy study only, not qualifying for CR, ie, both neutrophil >=0.5*10^9/L and platelets >=50*10^9/L must be met, but does not satisfy both neutrophils >=1*10^9/L and platelets >=100*10^9/L at the same time; absence of extramedullary disease; and absence of blasts with Auer rods.
Query!
Timepoint [13]
0
0
Day 1 up to maximum of 3 years
Query!
Secondary outcome [14]
0
0
Intensive Study: Duration of Response (DoRi)
Query!
Assessment method [14]
0
0
DoRi: only defined for participants who have ever achieved CRi or better (included CR as well) on study as the time from date of first achieving CRi or better to the date of relapse after CRi or better or death due to any cause. CRi: not qualifying for CR, neutropenia <1.0*10^9/L or platelets <100*10^9, absence of extramedullary disease, and absence of blasts with Auer rods. CR was defined based on 2017 ELN recommendations. CR: Bone marrow blasts <5 %; absence of circulating blasts and blasts with Auer rods; absence of extramedullary disease; ANC >=1.0*10^9/L; platelet count >=100*10^9/L. Participants last known to be alive who were free from relapse after CRi or better were censored at the date of last disease assessment that verifies their status.
Query!
Timepoint [14]
0
0
From date of first achieving CRi or better to the date of relapse after CRi or better or death due to any cause (maximum up to 2 years)
Query!
Secondary outcome [15]
0
0
Non-intensive Study: Duration of Response (DoRi) or (DoRh)
Query!
Assessment method [15]
0
0
DoRi: only defined for participants who have ever achieved CRi or better (included CR and CRh) on study as the time from date of first achieving CRi or better to the date of relapse after CRi or better or death due to any cause. DoRh: participants who had ever achieved CRh or better (included CR) on study as the time from date of first achieving CRh or better to the date of disease progression, or relapse after CRh or better, or death due to any cause. CRi: not qualifying for CR, neutrophil <0.5*10^9/L or platelets <50*10^9, absence of extramedullary disease, and absence of blasts with Auer rods. CRh: MRD (positive or unknown); bone marrow blasts <5%; assessed in non-intensive chemotherapy study only, not qualifying for CR, ie, both neutrophil >=0.5*10^9/L and platelets >=50*10^9/L must be met, but does not satisfy both neutrophils >=1*10^9/L and platelets >=100*10^9/L at the same time; absence of extramedullary disease; and absence of blasts with Auer rods.
Query!
Timepoint [15]
0
0
From date of first achieving CRi/CRh or better to the date of relapse/disease progression after CRi/CRh or better or death due to any cause (maximum up to 3 years)
Query!
Secondary outcome [16]
0
0
Non-intensive Study: Time to Response
Query!
Assessment method [16]
0
0
TTRi:Participants who achieved CRi or better, as the time from date of randomization to first documentation of response(CRi or better).TTRh:Participants who achieved CRh or better, as the time from date of randomization to first documentation of response(CRh or better). CRi:not qualifying for CR, neutrophil<0.5*10^9/L or platelets<50*10^9, absence of extramedullary disease,absence of blasts with Auer rods. CR was defined based on 2017 ELN recommendations. CR: Bone marrow blasts <5 %; absence of circulating blasts and blasts with Auer rods; absence of extramedullary disease; ANC >=1.0*10^9/L; platelet count >=100*10^9/L. CRh: MRD (positive or unknown); bone marrow blasts <5%; assessed in non-intensive chemotherapy study only, not qualifying for CR, ie, both neutrophil >=0.5*10^9/L and platelets >=50*10^9/L must be met, but does not satisfy both neutrophils >=1*10^9/L and platelets >=100*10^9/L at the same time; absence of extramedullary disease; and absence of blasts with Auer rods.
Query!
Timepoint [16]
0
0
From the date of randomization to the first documentation of response (CRi/CRh or better) (maximum up to 3 years)
Query!
Secondary outcome [17]
0
0
Intensive Study: Event-free Survival (EFS)
Query!
Assessment method [17]
0
0
EFS: Time from the date of randomization to the date of treatment failure (TF), relapse from CR, or death from any cause, whichever comes first. TF was defined as failure to achieve CR during the induction cycle (including the re-induction cycle if there is one) and the event date for TF is the day of randomization. CR was defined based on 2017 ELN recommendations. CR: Bone marrow blasts <5%; absence of circulating blasts and blasts with Auer rods; absence of extramedullary disease; ANC >=1.0*10^9/L; platelet count >=100*10^9/L.
Query!
Timepoint [17]
0
0
From the date of randomization to the date of TF, relapse from CR, or death from any cause, whichever comes first (maximum up to 2 years)
Query!
Secondary outcome [18]
0
0
Non-intensive Study: Event-free Survival (EFS)
Query!
Assessment method [18]
0
0
EFS: Time from the date of randomization to the date of TF, relapse from CR, or death from any cause, whichever comes first. TF was defined as failure to achieve CR during the induction cycle (including the re-induction cycle if there is one) and the event date for TF is the day of randomization. CR was defined based on 2017 ELN recommendations. CR: Bone marrow blasts <5%; absence of circulating blasts and blasts with Auer rods; absence of extramedullary disease; ANC >=1.0*10^9/L; platelet count >=100*10^9/L.
Query!
Timepoint [18]
0
0
From the date of randomization to the date of TF, relapse from CR, or death from any cause, whichever comes first (maximum up to 3 years)
Query!
Secondary outcome [19]
0
0
Intensive Study: MD Anderson Symptom Inventory -Acute Myelogenous Leukemia/Myelodysplastic Syndrome (MDASI-AML/MDS) Score
Query!
Assessment method [19]
0
0
MDASI-AML/MDS: consists of 23 items, 13-item core cancer symptoms (pain, fatigue, nausea, disturbed sleep, distress, shortness of breath, problem remembering, lack of appetite, drowsiness, dry mouth, sadness, vomiting, and numbness), 4-item AML/MDS specific symptoms (malaise, diarrhea, muscle weakness, and skin problems), and 6 areas of interference (general activity, mood, work, walking, relations with other people, and enjoyment of life). The 13 core symptoms and 6 core interference items had highest frequency and/or severity in participants with various cancers and treatment types. It was measured at severity of symptoms and related interference at their worst level in last 24 hours by asking participants to respond to each item on an 0-10 NRS, where 0 = "not present" or "did not interfere" and 10 = "worst" or "interfered completely".
Query!
Timepoint [19]
0
0
Day 1 up to maximum of 2 years
Query!
Secondary outcome [20]
0
0
Non-intensive Study: MD Anderson Symptom Inventory -Acute Myelogenous Leukemia/Myelodysplastic Syndrome (MDASI-AML/MDS) Score
Query!
Assessment method [20]
0
0
MDASI-AML/MDS: consists of 23 items, 13-item core cancer symptoms (pain, fatigue, nausea, disturbed sleep, distress, shortness of breath, problem remembering, lack of appetite, drowsiness, dry mouth, sadness, vomiting, and numbness), 4-item AML/MDS specific symptoms (malaise, diarrhea, muscle weakness, and skin problems), and 6 areas of interference (general activity, mood, work, walking, relations with other people, and enjoyment of life). The 13 core symptoms and 6 core interference items had highest frequency and/or severity in participants with various cancers and treatment types. It was measured at severity of symptoms and related interference at their worst level in last 24 hours by asking participants to respond to each item on an 0-10 NRS, where 0 = "not present" or "did not interfere" and 10 = "worst" or "interfered completely".
Query!
Timepoint [20]
0
0
Day 1 up to maximum of 3 years
Query!
Secondary outcome [21]
0
0
Intensive Study: EuroQoL 5 Dimension Questionnaire 5-Level Version (EQ-5D-5L) Score
Query!
Assessment method [21]
0
0
EQ-5D-5L: brief, self-administered, validated and reliable generic health status instrument developed by the EuroQoL Group. It consists of the EQ-5D descriptive system and a visual analogue scale (VAS), the EuroQoL visual analogue scale (EQ-VAS). EQ-5D: descriptive system measures a participant's health state on 5 dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression). Participant is asked to indicate his/her health state by rating each dimension on a 5-level scale (1=no problem, 5=extreme problem). This rating resulted in a 1-digit number expressing the level selected for that dimension. The digits for the 5 dimensions were combined in a 5-digit number describing the respondent's health state. The EQ-5D index scores ranges from 0 to 1, with 0=worst health state and 1=perfect health.
Query!
Timepoint [21]
0
0
Day 1 up to maximum of 2 years
Query!
Secondary outcome [22]
0
0
Non-intensive Study: EuroQoL 5 Dimension Questionnaire 5-Level Version (EQ-5D-5L) Score
Query!
Assessment method [22]
0
0
EQ-5D-5L: brief, self-administered, validated and reliable generic health status instrument developed by the EuroQoL group. It consists of the EQ-5D descriptive system and a VAS, EQ-VAS. EQ-5D: descriptive system measures a participant's health state on 5 dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression). Participant is asked to indicate his/her health state by rating each dimension on a 5-level scale (1=no problem, 5=extreme problem). This rating resulted in a 1-digit number expressing the level selected for that dimension. The digits for the 5 dimensions were combined in a 5-digit number describing the respondent's health state. The EQ-5D index scores ranges from 0 to 1, with 0=worst health state and 1=perfect health.
Query!
Timepoint [22]
0
0
Day 1 up to maximum of 3 years
Query!
Secondary outcome [23]
0
0
Intensive Study: EuroQoL Visual Analogue Scale (EQ-VAS)
Query!
Assessment method [23]
0
0
EQ-5D-5L: brief, self-administered, validated and reliable generic health status instrument developed by the EuroQoL group. It consists of the EQ-5D descriptive system and a VAS, EQ-VAS. EQ VAS records the respondent's self-rated health on a 20-cm vertical, VAS from 0 (worst imaginable health state) to 100 (best imaginable health state).
Query!
Timepoint [23]
0
0
Day 1 up to maximum of 2 years
Query!
Secondary outcome [24]
0
0
Non-intensive Study: EuroQoL Visual Analogue Scale (EQ-VAS)
Query!
Assessment method [24]
0
0
EQ-5D-5L: brief, self-administered, validated and reliable generic health status instrument developed by the EuroQoL group. It consists of the EQ-5D descriptive system and a VAS, EQ-VAS. EQ VAS records the respondent's self-rated health on a 20-cm vertical, VAS from 0 (worst imaginable health state) to 100 (best imaginable health state).
Query!
Timepoint [24]
0
0
Day 1 up to maximum of 3 years
Query!
Secondary outcome [25]
0
0
Intensive Study: Participants Global Impression of Symptoms (PGIS)
Query!
Assessment method [25]
0
0
PGIS: is a single 1-item questionnaire designed to assess participant's overall impression of disease severity at a given point in time. It uses a 4-point Likert scale as follows: In the last 24 hours, symptoms are: 1-"absent (no symptoms)", 2-"mild", 3-" moderate", 4="severe".
Query!
Timepoint [25]
0
0
Day 1 up to maximum of 2 years
Query!
Secondary outcome [26]
0
0
Non-intensive Study: Participants Global Impression of Symptoms (PGIS)
Query!
Assessment method [26]
0
0
PGIS: is a single 1-item questionnaire designed to assess participant's overall impression of disease severity at a given point in time. It uses a 4-point Likert scale as follows: In the last 24 hours, symptoms are: 1-"absent (no symptoms)", 2-"mild", 3-" moderate", 4="severe".
Query!
Timepoint [26]
0
0
Day 1 up to maximum of 3 years
Query!
Secondary outcome [27]
0
0
Intensive Study: Participants Global Impression of Change (PGIC)
Query!
Assessment method [27]
0
0
PGIC: a single-item questionnaire designed to assess the participant's overall sense of whether there has been a change since starting treatment as rated on a 7-point Likert scale anchored by (1) 'very much improved' to (7) 'very much worse', with (4) =' no change'. The PGIC is a measure of "participant rating of global improvement and satisfaction with treatment".
Query!
Timepoint [27]
0
0
Day 1 up to maximum of 2 years
Query!
Secondary outcome [28]
0
0
Non-intensive Study: Participants Global Impression of Change (PGIC)
Query!
Assessment method [28]
0
0
PGIC: a single-item questionnaire designed to assess the participant's overall sense of whether there has been a change since starting treatment as rated on a 7-point Likert scale anchored by (1) 'very much improved' to (7) 'very much worse', with (4) =' no change'. The PGIC is a measure of "participant rating of global improvement and satisfaction with treatment".
Query!
Timepoint [28]
0
0
Day 1 up to maximum of 3 years
Query!
Secondary outcome [29]
0
0
Intensive Study: Number of Participants With Adverse Events (AEs),Serious Adverse Events (SAEs) and According to Severity AEs Graded by NCI CTCAE v.4.03
Query!
Assessment method [29]
0
0
AE: any untoward medical occurrence in participant who received study drug without regard to possibility of causal relationship. SAE: any AE, regardless of dose, that led to death; was life-threatening; required hospitalization or prolonged hospitalization; led to persistent or significant incapacity or led to congenital anomaly or birth defect. AEs included SAEs and all non-SAEs. NCI CTCAE v.4.03, Grade 3=severe adverse event, Grade 4= life threatening consequences; urgent intervention indicated, Grade 5= death related to adverse event.
Query!
Timepoint [29]
0
0
Day 1 up to maximum of 2 years
Query!
Secondary outcome [30]
0
0
Non-intensive Study: Number of Participants With Adverse Events (AEs),Serious Adverse Events (SAEs) and According to Severity AEs Graded by NCI CTCAE v.4.03
Query!
Assessment method [30]
0
0
AE: any untoward medical occurrence in participant who received study drug without regard to possibility of causal relationship. SAE: any AE, regardless of dose, that led to death; was life-threatening; required hospitalization or prolonged hospitalization; led to persistent or significant incapacity or led to congenital anomaly or birth defect. AEs included SAEs and all non-SAEs. NCI CTCAE v.4.03, Grade 3=severe adverse event, Grade 4= life threatening consequences; urgent intervention indicated, Grade 5= death related to adverse event.
Query!
Timepoint [30]
0
0
Day 1 up to maximum of 3 years
Query!
Secondary outcome [31]
0
0
Intensive Study: Number of Participants With Treatment Related Adverse Events (AEs) and Serious Adverse Events (SAEs) Graded by NCI CTCAE v.4.03
Query!
Assessment method [31]
0
0
A treatment-related AE was any untoward medical occurrence attributed to the study drug in a participant who received study drug. SAE: any AE, regardless of dose, that led to death; was life-threatening; required hospitalization or prolonged hospitalization; led to persistent or significant incapacity or led to congenital anomaly or birth defect. NCI CTCAE v.4.03, Grade 3=severe adverse event, Grade 4= life threatening consequences; urgent intervention indicated, Grade 5= death related to adverse event.
Query!
Timepoint [31]
0
0
Day 1 up to maximum of 2 years
Query!
Secondary outcome [32]
0
0
Non-intensive Study: Number of Participants With Treatment Related Adverse Events (AEs) and Serious Adverse Events (SAEs) Graded by NCI CTCAE v.4.03
Query!
Assessment method [32]
0
0
A treatment-related AE was any untoward medical occurrence attributed to the study drug in a participant who received study drug. SAE: any AE, regardless of dose, that led to death; was life-threatening; required hospitalization or prolonged hospitalization; led to persistent or significant incapacity or led to congenital anomaly or birth defect. NCI CTCAE v4.03, Grade 3=severe adverse event, Grade 4= life threatening consequences; urgent intervention indicated, Grade 5= death related to adverse event.
Query!
Timepoint [32]
0
0
Day 1 up to maximum of 3 years
Query!
Secondary outcome [33]
0
0
Intensive Study: Number of Participants With Shift From Baseline in Hematological Laboratory Abnormalities Graded by NCI CTCAE v.4.03
Query!
Assessment method [33]
0
0
Hematology laboratory test included: anemia, hemoglobin increased, international normalized ratio (INR) increased, lymphocyte count decreased, lymphocyte count increased, neutrophil count decreased, platelet count decreased, and white blood cell decreased. Laboratory results were categorically summarized according to the NCI-CTCAE criteria v4.03. Grade 1= mild; Grade 2= moderate; Grade 3= severe and Grade 4= life-threatening or disabling. Number of participants with shift from baseline for hematology laboratory test were assessed. Only those laboratory test parameters in which at least 1 participant had data were reported.
Query!
Timepoint [33]
0
0
Day 1 up to maximum of 2 years
Query!
Secondary outcome [34]
0
0
Non-intensive Study: Number of Participants With Shift From Baseline in Hematological Laboratory Abnormalities Graded by NCI CTCAE v.4.03
Query!
Assessment method [34]
0
0
Hematology laboratory test included: anemia, hemoglobin increased, INR increased, lymphocyte count decreased, lymphocyte count increased, neutrophil count decreased, platelet count decreased, and white blood cell decreased. Laboratory results were categorically summarized according to the NCI-CTCAE criteria v4.03. Grade 1= mild; Grade 2= moderate; Grade 3= severe and Grade 4= life-threatening or disabling. Number of participants with shift from baseline for hematology laboratory test were assessed. Only those laboratory test parameters in which at least 1 participant had data were reported.
Query!
Timepoint [34]
0
0
Day 1 up to maximum of 3 years
Query!
Secondary outcome [35]
0
0
Intensive Study: Number of Participants With Shift From Baseline in Chemistry Laboratory Abnormalities Graded by NCI CTCAE v.4.03
Query!
Assessment method [35]
0
0
Chemistry laboratory test included: alanine aminotransferase increased, alkaline phosphatase increased, aspartate aminotransferase increased, blood bilirubin increased, chronic kidney disease, creatine phosphokinase (CPK) increased, creatinine increased, gamma glutamyl transferase (GGT) increased, hypercalcemia, hyperglycemia, hyperkalemia, hypermagnesemia, hypernatremia, hypoalbuminemia, hypocalcemia, hypoglycemia, hypokalemia, hypomagnesemia, hyponatremia, and hypophosphatemia. Laboratory results were categorically summarized according to the NCI-CTCAE criteria v4.03. Grade 1= mild; Grade 2= moderate; Grade 3= severe and Grade 4= life-threatening or disabling. Number of participants with shift from baseline for chemistry laboratory test were assessed. Only those laboratory test parameters in which at least 1 participant had data were reported.
Query!
Timepoint [35]
0
0
Day 1 up to maximum of 2 years
Query!
Secondary outcome [36]
0
0
Non-intensive Study: Number of Participants With Shift From Baseline in Chemistry Laboratory Abnormalities Graded by NCI CTCAE v.4.03
Query!
Assessment method [36]
0
0
Chemistry laboratory test included: alanine aminotransferase increased, alkaline phosphatase increased, aspartate aminotransferase increased, blood bilirubin increased, chronic kidney disease, CPK increased, creatinine increased, GGT increased, hypercalcemia, hyperglycemia, hyperkalemia, hypermagnesemia, hypernatremia, hypoalbuminemia, hypocalcemia, hypoglycemia, hypokalemia, hypomagnesemia, hyponatremia, and hypophosphatemia. Laboratory results were categorically summarized according to the NCI-CTCAE criteria v4.03. Grade 1= mild; Grade 2= moderate; Grade 3= severe and Grade 4= life-threatening or disabling. Number of participants with shift from baseline for chemistry laboratory test were assessed. Only those laboratory test parameters in which at least 1 participant had data were reported.
Query!
Timepoint [36]
0
0
Day 1 up to maximum of 3 years
Query!
Secondary outcome [37]
0
0
Intensive Study: Number of Participants With Shift From Baseline in Coagulation Laboratory Abnormalities Graded by NCI CTCAE v.4.03
Query!
Assessment method [37]
0
0
Coagulation laboratory test included: activated partial thromboplastin time prolonged, and INR increased. Laboratory results were categorically summarized according to the NCI-CTCAE criteria v4.03. Grade 0= no abnormality; Grade 1= mild; Grade 2= moderate; Grade 3= severe and Grade 4= life-threatening or disabling. Number of participants with shift from baseline for coagulation were assessed. Only those laboratory test parameters in which at least 1 participant had data were reported.
Query!
Timepoint [37]
0
0
Day 1 up to maximum of 2 years
Query!
Secondary outcome [38]
0
0
Non-intensive Study: Number of Participants With Shift From Baseline in Coagulation Laboratory Abnormalities Graded by NCI CTCAE v.4.03
Query!
Assessment method [38]
0
0
Coagulation laboratory test included: activated partial thromboplastin time prolonged, and INR increased. Laboratory results were categorically summarized according to the NCI-CTCAE criteria v4.03. Grade 0= no abnormality; Grade 1= mild; Grade 2= moderate; Grade 3= severe and Grade 4= life-threatening or disabling. Number of participants with shift from baseline for coagulation were assessed. Only those laboratory test parameters in which at least 1 participant had data were reported.
Query!
Timepoint [38]
0
0
Day 1 up to maximum of 3 years
Query!
Secondary outcome [39]
0
0
Intensive Study: Plasma Trough Concentration (Ctrough) of Glasdegib
Query!
Assessment method [39]
0
0
Ctrough of Glasdegib was measured in nanogram per milliliter (ng/mL).
Query!
Timepoint [39]
0
0
Induction, Day 10+/-1: pre-dose, 1, 4 hour (hr); Consolidation phase, Day 1: pre-dose, 1, 4 hr
Query!
Secondary outcome [40]
0
0
Non-intensive Study: Plasma Trough Concentration (Ctrough) of Glasdegib
Query!
Assessment method [40]
0
0
Ctrough of Glasdegib was measured in ng/mL.
Query!
Timepoint [40]
0
0
Pre-dose: Cycle 1 Day 15 and Cycle 2 Day 1
Query!
Secondary outcome [41]
0
0
Intensive Study: Number of Participants With Shift From Baseline in Corrected QT (QTc) Interval
Query!
Assessment method [41]
0
0
Triplicate 12-lead ECG measurements (each recording separated by approximately 2 minutes) were performed and average was calculated. The time corresponding to beginning of depolarization to repolarization of the ventricles (QT interval) was adjusted for RR interval using QT and RR from each ECG by Fridericia's formula (QTcF = QT divided by cube root of RR) and by Bazette's formula (QTcB = QT divided by square root of RR). Participants with maximum increase from baseline of <=450 to >500 msec (post-baseline) were summarized. Number of participants with shift from baseline for QTc were assessed. Only those QTc parameters in which at least 1 participant had data were reported.
Query!
Timepoint [41]
0
0
Day 1 up to maximum of 2 years
Query!
Secondary outcome [42]
0
0
Non-intensive Study: Number of Participants With Shift From Baseline in Corrected QT (QTc) Interval
Query!
Assessment method [42]
0
0
Triplicate 12-lead ECG measurements (each recording separated by approximately 2 minutes) were performed and average was calculated. The time corresponding to beginning of depolarization to repolarization of the ventricles (QT interval) was adjusted for RR interval using QT and RR from each ECG by Fridericia's formula (QTcF = QT divided by cube root of RR) and by Bazette's formula (QTcB = QT divided by square root of RR). Participants with maximum increase from baseline of <=450 to >500 msec (post-baseline) were summarized. Number of participants with shift from baseline for QTc were assessed. Only those QTc parameters in which at least 1 participant had data were reported.
Query!
Timepoint [42]
0
0
Day 1 up to maximum of 3 years
Query!
Eligibility
Key inclusion criteria
Subjects must meet all of the following inclusion criteria to be eligible for enrollment
into the Intensive and Non Intensive study (unless where indicated):
1. Subjects with untreated AML according to the World Health Organization (WHO) 2016
Classification2, including those with:
- AML arising from MDS or another antecedent hematologic disease (AHD).
- AML after previous cytotoxic therapy or radiation (secondary AML).
2. 18 years of age (In Japan, 20 years of age).
3. Adequate Organ Function as defined by the following:
- Serum aspartate aminotransferase (AST) and serum alanine aminotransferase (ALT) 3
x upper limit of normal (ULN), excluding subjects with liver function
abnormalities due to underlying malignancy.
- Total serum bilirubin 2 x ULN (except subjects with documented Gilbert's
syndrome).
- Estimated creatinine clearance 30 mL/min as calculated using the standard method
for the institution.
4. QTc interval 470 msec using the Fridericia correction (QTcF).
5. All anti cancer treatments (unless specified) should be discontinued 2 weeks from
study entry, for example: targeted chemotherapy, radiotherapy, investigational agents,
hormones, anagrelide or cytokines.
- For control of rapidly progressing leukemia, all trans retinoic acid (ATRA),
hydroxyurea, and/or leukopheresis may be used before and for up to 1 week after
the first dose of glasdegib.
6. Serum or urine pregnancy test (for female subjects of childbearing potential) with a
minimum sensitivity of 25 IU/L or equivalent units of human chorionic gonadotropin
(hCG) negative at screening.
7. Male and female subjects of childbearing potential and at risk for pregnancy must
agree to use at least one highly effective method of contraception throughout the
study and for 180 days after the last dose of azacitidine, cytarabine, or
daunorubicin; and the last dose of glasdegib or placebo, whichever occurs later.
8. Female subjects of non childbearing potential must meet at least 1 of the following
criteria:
1. Have undergone a documented hysterectomy and/or bilateral oophorectomy;
2. Have medically confirmed ovarian failure; or
3. Achieved postmenopausal status, defined as follows: cessation of regular menses
for at least 12 consecutive months with no alternative pathological or
physiological cause; status may be confirmed by having a serum follicle
stimulating hormone (FSH) level confirming the postmenopausal state.
All other female subjects (including female subjects with tubal ligations) are
considered to be of childbearing potential.
9. Consent to a saliva sample collection for a germline comparator, unless prohibited by
local regulations or ethics committee (EC) decision.
10. Evidence of a personally signed and dated informed consent document indicating that
the patient has been informed of all pertinent aspects of the study.
11. Subjects who are willing and able to comply with the study scheduled visits, treatment
plans, laboratory tests and other procedures (including bone marrow [BM] assessments).
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
Subjects with any of the following characteristics/conditions will not be included in the
study:
1. Acute Promyelocytic Leukemia (APL) and APLwith PML RARA, subjects (WHO 2016
classification).
2. AML with BCR ABL1 or t(9;22)(q34;q11.2) as a sole abnormality.
- Complex genetics may include t(9;22) cytogenetic translocation.
3. Subjects with known active CNS leukemia.
4. Participation in other clinical studies involving other investigational drug(s)
(Phases 1 4) within 4 weeks prior study entry and/or during study participation.
5. Subjects known to be refractory to platelet or packed red cell transfusions per
Institutional Guidelines, or a patient who refuses blood product support.
6. Subjects with another active malignancy on treatment with the exception of basal cell
carcinoma, non melanoma skin cancer, cervical carcinoma in situ. Other prior or
concurrent malignancies will be considered on a case by case basis.
7. Any one of the following ongoing or in the previous 6 months: myocardial infarction,
congenital long QT syndrome, Torsades de pointes, symptomatic arrhythmias (including
sustained ventricular tachyarrhythmia), right or left bundle branch block and
bifascicular block, unstable angina, coronary/peripheral artery bypass graft,
symptomatic congestive heart failure (CHF New York Heart Association class III or IV),
cerebrovascular accident, transient ischemic attack or symptomatic pulmonary embolism;
as well as bradycardia defined as <50 bpms.
8. Subjects with an active, life threatening or clinically significant uncontrolled
systemic infection not related to AML.
9. Subjects with left ventricular ejection fraction (LVEF) <50% are excluded from the
Intensive Chemotherapy Study only.
10. Cumulative anthracycline dose equivalent of 550 mg/m2 of daunorubicin for the
Intensive Chemotherapy Study only.
11. Known malabsorption syndrome or other condition that may significantly impair
absorption of study medication in the investigator's judgment (eg, gastrectomy, lap
band, Crohn's disease) and inability or unwillingness to swallow tablets or capsules.
12. Current use or anticipated requirement for drugs that are known strong CYP3A4/5
inducers.
13. Concurrent administration of herbal preparations.
14. Major surgery or radiation within 4 weeks of starting study treatment.
15. Documented or suspected hypersensitivity to any one of the following:
- For subjects assigned to intensive chemotherapy, documented or suspected
hypersensitivity to cytarabine (not including drug fever or exanthema, including
known cerebellar side effects) or daunorubicin.
- For subjects assigned to non intensive chemotherapy, documented or suspected
hypersensitivity to azacitidine or mannitol.
16. Known active drug or alcohol abuse.
17. Other acute or chronic medical or psychiatric condition including recent (within the
past year) or active suicidal ideation or behavior or laboratory abnormality that may
increase the risk associated with study participation or investigational product
administration or may interfere with the interpretation of study results and, in the
judgment of the investigator, would make the subject inappropriate for entry into this
study.
18. Pregnant females or breastfeeding female subjects.
19. Known recent or active suicidal ideation or behavior.
20. Investigator site staff members directly involved in the conduct of the study and
their family members, site staff members otherwise supervised by the investigator, or
subjects who are Pfizer employees, including their family members, directly involved
in the conduct of the study.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
20/04/2018
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
17/01/2022
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
730
Query!
Recruitment in Australia
Recruitment state(s)
NSW,SA
Query!
Recruitment hospital [1]
0
0
St Vincent's Hospital Sydney - Darlinghurst
Query!
Recruitment hospital [2]
0
0
St George Hospital - Kogarah
Query!
Recruitment hospital [3]
0
0
Royal Adelaide Hospital - Adelaide
Query!
Recruitment postcode(s) [1]
0
0
2010 - Darlinghurst
Query!
Recruitment postcode(s) [2]
0
0
2217 - Kogarah
Query!
Recruitment postcode(s) [3]
0
0
5000 - Adelaide
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
California
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Georgia
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Massachusetts
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Missouri
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
New York
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Ohio
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Oregon
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Tennessee
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Texas
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
Washington
Query!
Country [11]
0
0
Austria
Query!
State/province [11]
0
0
Salzburg
Query!
Country [12]
0
0
Austria
Query!
State/province [12]
0
0
Wien
Query!
Country [13]
0
0
Belgium
Query!
State/province [13]
0
0
Brugge
Query!
Country [14]
0
0
Belgium
Query!
State/province [14]
0
0
Brussels
Query!
Country [15]
0
0
Belgium
Query!
State/province [15]
0
0
Leuven
Query!
Country [16]
0
0
Canada
Query!
State/province [16]
0
0
Manitoba
Query!
Country [17]
0
0
Canada
Query!
State/province [17]
0
0
Ontario
Query!
Country [18]
0
0
Canada
Query!
State/province [18]
0
0
Quebec
Query!
Country [19]
0
0
Canada
Query!
State/province [19]
0
0
Saskatchewan
Query!
Country [20]
0
0
China
Query!
State/province [20]
0
0
Anhui
Query!
Country [21]
0
0
China
Query!
State/province [21]
0
0
Fujian
Query!
Country [22]
0
0
China
Query!
State/province [22]
0
0
Guangdong
Query!
Country [23]
0
0
China
Query!
State/province [23]
0
0
Hebei
Query!
Country [24]
0
0
China
Query!
State/province [24]
0
0
Henan
Query!
Country [25]
0
0
China
Query!
State/province [25]
0
0
Hubei
Query!
Country [26]
0
0
China
Query!
State/province [26]
0
0
Sichuan
Query!
Country [27]
0
0
China
Query!
State/province [27]
0
0
Tianjin
Query!
Country [28]
0
0
China
Query!
State/province [28]
0
0
Zhejiang
Query!
Country [29]
0
0
China
Query!
State/province [29]
0
0
Shanghai
Query!
Country [30]
0
0
Czechia
Query!
State/province [30]
0
0
Brno
Query!
Country [31]
0
0
Czechia
Query!
State/province [31]
0
0
Ostrava - Poruba
Query!
Country [32]
0
0
Czechia
Query!
State/province [32]
0
0
Ostrava-Poruba
Query!
Country [33]
0
0
Czechia
Query!
State/province [33]
0
0
Praha 10
Query!
Country [34]
0
0
France
Query!
State/province [34]
0
0
Créteil
Query!
Country [35]
0
0
France
Query!
State/province [35]
0
0
Nantes cedex 1
Query!
Country [36]
0
0
France
Query!
State/province [36]
0
0
Nantes cedex
Query!
Country [37]
0
0
France
Query!
State/province [37]
0
0
Paris
Query!
Country [38]
0
0
France
Query!
State/province [38]
0
0
Pierre-Benite cedex
Query!
Country [39]
0
0
France
Query!
State/province [39]
0
0
Villejuif cedex
Query!
Country [40]
0
0
Germany
Query!
State/province [40]
0
0
Bavaria
Query!
Country [41]
0
0
Germany
Query!
State/province [41]
0
0
Hesse
Query!
Country [42]
0
0
Germany
Query!
State/province [42]
0
0
North Rhine Westphalia
Query!
Country [43]
0
0
Germany
Query!
State/province [43]
0
0
North Rhine-westphalia
Query!
Country [44]
0
0
Germany
Query!
State/province [44]
0
0
Hamburg
Query!
Country [45]
0
0
Germany
Query!
State/province [45]
0
0
Hannover
Query!
Country [46]
0
0
Hungary
Query!
State/province [46]
0
0
Debrecen
Query!
Country [47]
0
0
Hungary
Query!
State/province [47]
0
0
Gyor
Query!
Country [48]
0
0
Hungary
Query!
State/province [48]
0
0
Kaposvar
Query!
Country [49]
0
0
Hungary
Query!
State/province [49]
0
0
Nyiregyhaza
Query!
Country [50]
0
0
Israel
Query!
State/province [50]
0
0
Haifa
Query!
Country [51]
0
0
Israel
Query!
State/province [51]
0
0
Jerusalem
Query!
Country [52]
0
0
Israel
Query!
State/province [52]
0
0
Petah Tikva
Query!
Country [53]
0
0
Italy
Query!
State/province [53]
0
0
Ancona
Query!
Country [54]
0
0
Italy
Query!
State/province [54]
0
0
AN
Query!
Country [55]
0
0
Italy
Query!
State/province [55]
0
0
FE
Query!
Country [56]
0
0
Italy
Query!
State/province [56]
0
0
PU
Query!
Country [57]
0
0
Italy
Query!
State/province [57]
0
0
SI
Query!
Country [58]
0
0
Italy
Query!
State/province [58]
0
0
Bologna
Query!
Country [59]
0
0
Italy
Query!
State/province [59]
0
0
Siena
Query!
Country [60]
0
0
Japan
Query!
State/province [60]
0
0
Aichi
Query!
Country [61]
0
0
Japan
Query!
State/province [61]
0
0
Fukui
Query!
Country [62]
0
0
Japan
Query!
State/province [62]
0
0
Gunma
Query!
Country [63]
0
0
Japan
Query!
State/province [63]
0
0
Hyogo
Query!
Country [64]
0
0
Japan
Query!
State/province [64]
0
0
Kanagawa
Query!
Country [65]
0
0
Japan
Query!
State/province [65]
0
0
Miyagi
Query!
Country [66]
0
0
Japan
Query!
State/province [66]
0
0
Osaka
Query!
Country [67]
0
0
Japan
Query!
State/province [67]
0
0
Shizuoka
Query!
Country [68]
0
0
Japan
Query!
State/province [68]
0
0
Tokyo
Query!
Country [69]
0
0
Japan
Query!
State/province [69]
0
0
Akita
Query!
Country [70]
0
0
Japan
Query!
State/province [70]
0
0
Fukuoka
Query!
Country [71]
0
0
Japan
Query!
State/province [71]
0
0
Kumamoto
Query!
Country [72]
0
0
Japan
Query!
State/province [72]
0
0
Nagasaki
Query!
Country [73]
0
0
Korea, Republic of
Query!
State/province [73]
0
0
Jeollabuk-do
Query!
Country [74]
0
0
Korea, Republic of
Query!
State/province [74]
0
0
Busan
Query!
Country [75]
0
0
Korea, Republic of
Query!
State/province [75]
0
0
Daegu
Query!
Country [76]
0
0
Korea, Republic of
Query!
State/province [76]
0
0
Incheon
Query!
Country [77]
0
0
Korea, Republic of
Query!
State/province [77]
0
0
Seoul
Query!
Country [78]
0
0
Mexico
Query!
State/province [78]
0
0
MÉX
Query!
Country [79]
0
0
Mexico
Query!
State/province [79]
0
0
Nuevo LEON
Query!
Country [80]
0
0
Poland
Query!
State/province [80]
0
0
Gdansk
Query!
Country [81]
0
0
Poland
Query!
State/province [81]
0
0
Lodz
Query!
Country [82]
0
0
Romania
Query!
State/province [82]
0
0
Cluj
Query!
Country [83]
0
0
Romania
Query!
State/province [83]
0
0
Dolj
Query!
Country [84]
0
0
Romania
Query!
State/province [84]
0
0
Bucharest
Query!
Country [85]
0
0
Romania
Query!
State/province [85]
0
0
Bucuresti
Query!
Country [86]
0
0
Russian Federation
Query!
State/province [86]
0
0
Moscow
Query!
Country [87]
0
0
Russian Federation
Query!
State/province [87]
0
0
Nizhniy Novgorod
Query!
Country [88]
0
0
Russian Federation
Query!
State/province [88]
0
0
Ryazan
Query!
Country [89]
0
0
Russian Federation
Query!
State/province [89]
0
0
Saint Petersburg
Query!
Country [90]
0
0
Spain
Query!
State/province [90]
0
0
Barcelona
Query!
Country [91]
0
0
Spain
Query!
State/province [91]
0
0
Lleida
Query!
Country [92]
0
0
Spain
Query!
State/province [92]
0
0
Madrid
Query!
Country [93]
0
0
Spain
Query!
State/province [93]
0
0
Sevilla
Query!
Country [94]
0
0
Spain
Query!
State/province [94]
0
0
Valencia
Query!
Country [95]
0
0
Sweden
Query!
State/province [95]
0
0
Orebro
Query!
Country [96]
0
0
Sweden
Query!
State/province [96]
0
0
Stockholm
Query!
Country [97]
0
0
Taiwan
Query!
State/province [97]
0
0
Tainan
Query!
Country [98]
0
0
Taiwan
Query!
State/province [98]
0
0
Taipei
Query!
Country [99]
0
0
Taiwan
Query!
State/province [99]
0
0
Taoyuan City
Query!
Country [100]
0
0
United Kingdom
Query!
State/province [100]
0
0
Surrey
Query!
Country [101]
0
0
United Kingdom
Query!
State/province [101]
0
0
WEST Midlands
Query!
Country [102]
0
0
United Kingdom
Query!
State/province [102]
0
0
London
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
Pfizer
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
Glasdegib is being studied in combination with azacitidine for the treatment of adult
patients with previously untreated acute myeloid leukemia (AML) who are not candidates for
intensive induction chemotherapy (Non-intensive AML population).
Glasdegib is being studied in combination with cytarabine and daunorubicin for the treatment
of adult patients with previously untreated acute myeloid leukemia (Intensive AML
population).
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT03416179
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Pfizer CT.gov Call Center
Query!
Address
0
0
Pfizer
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT03416179
Download to PDF